Michael Kauffman, Chief Executive Officer at Karyopharm Therapeutics Inc. (KPTI), sold 20,000 shares at $17.02 ($330K) on 2019-12-09, disclosed to the SEC on 2019-12-11.
Open-market sale of $330k KPTI by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.02 | 10,000 | $170K | 51.6% |
| 2 | $15.99 | 10,000 | $160K | 48.4% |
| Total | $16.50 avg | 20,000 | $330K | 100% |
| Filing → |
| KPTI | SELL | 2022-03-02 | $128K | — | Filing → |
| KPTI | SELL | 2022-02-22 | $440K | — | Filing → |
| KPTI | SELL | 2022-02-09 | $266K | — | Filing → |